Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the colon or rectum * Advanced or metastatic disease * Must have received a fluoropyrimidine-based regimen and an irinotecan-based regimen, either alone or in combination, for advanced disease * May have relapsed within 6 months of adjuvant therapy with fluorouracil (5-FU) (or combination 5-FU and irinotecan) and progressed after single-agent irinotecan * Measurable disease * No known brain metastases * Performance status - ECOG 0-2 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * No history of thrombotic or hemorrhagic disorders * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * AST no greater than 5 times ULN * INR no greater than 1.5 * PTT no greater than ULN * Creatinine no greater than 1.5 times ULN * Proteinuria less than 1+ (i.e., 0 or trace) * Protein less than 500 mg by 24-hour urine collection * Proteinuria secondary to ureteral stents allowed * No proteinuria secondary to nephropathy * Controlled hypertension (less than 150/100 mm Hg) allowed if on a stable antihypertensive regimen * No prior myocardial infarction * No uncontrolled congestive heart failure * No unstable angina within the past 3 months * No serious nonhealing wound, ulcer, or bone fracture * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No prior bevacizumab * See Disease Characteristics * Recovered from prior chemotherapy * No prior oxaliplatin * At least 2 weeks since prior radiotherapy and recovered * At least 28 days since prior major surgical procedure * At least 10 days since prior aspirin dose of more than 325 mg/day * No concurrent therapeutic anticoagulation except prophylactic anticoagulation of venous access device * No concurrent antiplatelet agents (e.g., dipyridamole, ticlopidine, clopidogrel, or cilostazol) * No concurrent oral cryotherapy on day 1 of oxaliplatin administration